Medibio Announces Scientific Advisory Board
- Led by Board of Director Franklyn Prendergast, M.D., Ph.D. and Chief Medical Officer Archie Defillo, M.D.
- Key external members include Martin Chapman, M.D.; Joel Ehrenkranz, M.D.; Mark A. Frye, M.D.; Lawrence Hunter, Ph.D.; Wallace Mendelson, M.D.; Marie Casey Olseth, M.D., and Giampaolo Perna, M.D., Ph.D.
SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB).
Scientific Advisory Board Charter/Purpose
The Medibio Scientific Advisory Board is charged to advise the board of directors and executive leadership team on scientific matters involving the Company's discovery and development of programs, including major internal projects, interactions with academic and other outside research organizations, and the acquisition of technologies. The SAB will assist directors and management to stay abreast of industry and mental health research developments, new technologies, and anticipate emerging concepts and trends in mental health, to help assure that Medibio leadership makes well informed choices in committing its resources.
The SAB will also advise the board on scientific matters involving the safety and effectiveness of the Company's marketed products and will assist leadership to exercise reasonable oversight of product safety and medical risk management.
Jack Cosentino, CEO and Managing Director stated, "Our Scientific Advisory Board brings expertise in specialties ranging from computational informatics and neuroscience, to clinicians practicing in primary care and behavioral health. We are honored to have an advisory team with this high level of talent and experience guiding our scientific programs and advising our long-term strategic goals."
Scientific Advisory Board Members
Martin Chapman, MBBS FRANZCP is a psychiatrist and Fellow of the Royal Australian and New Zealand College of Psychiatrists. As a medical administrator he has worked in both hospital and community settings in private and government sectors. His clinical practice is in the area of treatment resistant mood and anxiety disorders. He has taught in undergraduate and postgraduate Psychiatry with a focus in assisting primary care physicians in their management of mental health conditions. He has an interest in mental health system development and the role of new technologies in streamlining and providing clinical decision support.
Joel R. Ehrenkranz, M.D. is an endocrinologist on the faculty of the U. of Colorado School of Medicine and biotech entrepreneur in Salt Lake City, Utah. He received his M.D. from Stanford and trained in internal medicine at Columbia University, neurology at Memorial Sloan Kettering Cancer Center, and endocrinology at the N.I.H.
Mark A. Frye, M.D. is chair of the Department of Psychiatry and Psychology at Mayo Clinic. He also serves as director of the Mayo Clinic Depression Center. Dr. Frye received his M.D. from the University of Minnesota and completed his psychiatric training at the Semel Institute for Neuroscience and Human Behavior at the David Geffen School of Medicine at UCLA. He subsequently completed a fellowship at the National Institute of Mental Health in Bethesda, Maryland with a research focus on the neurobiology of treatment resistant depression and bipolar disorder.
Lawrence Hunter, Ph.D. is a Professor at the University of Colorado and directs the Computational Bioscience Program. He earned his degrees from Yale University, including B.A. in Psychology (cum laude); M.S. and M. Phil. and Ph.D. in Computer Science.
Wallace Mendelson, M.D. is a psychiatrist and author, and was formerly Professor of Psychiatry and Clinical Pharmacology, and director of the Sleep Research Laboratory, at the University of Chicago. Dr. Mendelson earned an MD degree from Washington University School of Medicine in St. Louis and completed a residency in psychiatry there as well. He has held professorships at Ohio State University and the State University of New York at Stony Brook, was Chief of the Section on Sleep Studies at the National Institute of Mental Health in Bethesda, MD, and Director of the Sleep Disorders Center at the Cleveland Clinic.
Marie Casey Olseth, M.D. is currently in private practice as a Board Certified Adult Psychiatrist in the group practice that she owns. She earned her Doctor of Medicine degree from the University of Minnesota Medical School and completed her residency in General Psychiatry at the University of Minnesota and University of Wisconsin, Madison.
Giampaolo Perna, M.D., Ph.D. is currently Chair of the Department of Clinical Neurosciences at San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake) and Academic Coordinator of Mental Health Area and Adjunct Professor at Humanitas University (Milan), in Italy. He earned his degree in Medicine and Surgery at the State University of Milan, followed by a Ph.D. and completed a residency in Psychiatry there as well. He is the Chair of WPA section on personalized psychiatry and Co-editor in chief of the Elsevier Journal "Personalized Medicine in Psychiatry".
Archie Defillo, M.D. is currently the Chief Medical Officer at Medibio Limited. He has over 25 years of clinical experience with neurological diseases. For the past 13 years his efforts have been focused in neurological research. His research interests include cerebrovascular, stroke, neuro-trauma, brain oxygenation, metabolism and autonomic dysfunction.
Peta Slocombe, M.S. is a fully registered Psychologist, member of the Australian Psychological Society and a registered National Health Practitioner with over 20 years' experience. She is currently Senior Vice President, Corporate Health with Medibio Limited.
Franklyn Prendergast, M.D., Ph.D. is currently a director on the Medibio Limited board and chair of the Scientific Advisory Board. Previously, he was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.
Dr. Prendergast earned his medical degree with honors from the University of West Indies. He attended Oxford University as a Rhodes Scholar, where he earned his masters degree in Physiology. After completing residency in Internal medicine at The Mayo Clinic in Rochester, Minnesota he earned a doctorate degree Biochemistry from the University of Minnesota/Mayo Graduate School.
Positions held: Chair, Department of Biochemistry and Molecular Biology; Director for Research Mayo Clinic (Rochester) (1989-1992). Board of Governors Mayo Clinic in Rochester; Mayo Clinic Board of Trustees (1992-2009); Mayo Clinic Board of Governors (1999-2006). Mayo Distinguished Investigator; Emeritus Director, Mayo Clinic Comprehensive Cancer Center and Mayo Center for Individualized Medicine.
In addition to his current role as a director on the Medibio board and chair of the Scientific Advisory Board, Dr. Prendergast holds numerous appointments with Industry and Extramural academic affiliations. He has extensive interactions over many years with National Institutes of Health (NIH): Board of Advisors for the Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of the National Cancer Institute; and the National Cancer Advisory Board.
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Stephanie Ottens Investor Relations Director Medibio Limited email@example.com T: +61 434 405 400 Australian Media Enquiries: Peter Taylor NWR Communications firstname.lastname@example.org T: +61 (0) 412 036 231
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
TESARO Announces Data Presentations at ESMO 2018 Congress20.10.2018 07:30 | Pressemelding
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019 MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high (MSI-H) endometrial cancer presented during the European Society for Medical Oncology (ESMO) Congress. Blinded, pooled interim safety data from the Phase 3 PRIMA trial of niraparib in patients with first-line ovarian cancer regardless of biomarker status were also presented in a poster discussion session and additional data from the QUADRA trial of niraparib for treatment of late-li
The Navigators Group, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger19.10.2018 22:01 | Pressemelding
STAMFORD, Conn., Oct. 19, 2018 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) (“Navigators” or the “Company”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with its previously announced merger with a direct wholly owned subsidiary (“Merger Sub”) of The Hartford Financial Services Group, Inc. (“The Hartford”), expired at 11:59 p.m. Eastern Time on October 18, 2018. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the merger, which remains subject to other closing conditions in the Agreement and Plan of Merger, dated as of August 22, 2018, by and among the Company, The Hartford and Merger Sub. About Navigators The Navigators Group, Inc. (NASDAQ: NAVG) (“Navigators” or the “Company”) is a global specialty insurance holding company. We provide customized insurance solutions designed to protect clients from the complex risk
ATTO Technology introduces the XstreamCORE® FC 7600 32Gb Fibre Channel to 12Gb SAS Hardware Accelerated Storage Controller19.10.2018 15:00 | Pressemelding
AMHERST, N.Y., Oct. 19, 2018 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for 30 years, announces availability of the ATTO XstreamCORE® FC 7600 storage controller. ATTO XstreamCORE FC 7600 is a standalone, accelerated storage controller that connects any external SAS device, such as a JBOD of HDDs or SSDs, a RAID array or external tape devices, and presents them isolated to individual hosts or shared over a Fibre Channel SAN fabric. It includes ATTO exclusive technologies, ATTO xCORE hardware acceleration processor and ATTO intelligent Bridging Architecture™, that combine to keep latency astonishingly low at three microseconds. For less than the price of a performance server, XstreamCORE FC 7600 enables up to 64 Fibre Channel connected clients to remotely access and share up to 240 SAS/SATA SSD or HDD devices via JBOD or JBOF at direct attached speeds with consistent, d
Biome Grow Introduces PEI Brand, Red Sands Craft Cannabis Co.19.10.2018 13:30 | Pressemelding
TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO) (FSE:6OTA) is pleased to introduce its fifth subsidiary company and brand, Red Sands Craft Cannabis Co. (“Red Sands”). Red Sands is located in Prince Edward Island (PEI) and will service both the local and tourist markets in that province with locally produced and regionally grown cannabis products. The Red Sands Craft Cannabis Co. brand reflects PEI’s iconic red sand beaches and the craft goods and services that are produced locally. Visually, it balances the vibrant, energetic colours with the calm nature that PEI is known for, setting the stage for the tailored cannabis products that Red Sands will offer. Though the smallest Canadian province both in terms of land area and population, with approximately 153,000 residents living on the Island, the province has a robust tourism industry. In 2017, the province set records with more than 1,000,000 overnight stays, by an estimated 1.56 million
CORRECTION - Elite Petro & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited18.10.2018 23:35 | Pressemelding
DUBAI, United Arab Emirates, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.
Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21 | Pressemelding
BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom